Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coya Therapeutics (COYA) EBT (2022 - 2025)

Coya Therapeutics' EBT history spans 4 years, with the latest figure at -$2.4 million for Q3 2025.

  • For Q3 2025, EBT rose 45.33% year-over-year to -$2.4 million; the TTM value through Sep 2025 reached -$19.9 million, down 88.25%, while the annual FY2024 figure was -$15.6 million, 114.77% down from the prior year.
  • EBT for Q3 2025 was -$2.4 million at Coya Therapeutics, up from -$6.1 million in the prior quarter.
  • Across five years, EBT topped out at $1.8 million in Q4 2023 and bottomed at -$7.3 million in Q1 2025.
  • The 4-year median for EBT is -$3.3 million (2023), against an average of -$3.3 million.
  • The largest annual shift saw EBT soared 190.6% in 2023 before it crashed 324.79% in 2024.
  • A 4-year view of EBT shows it stood at -$2.0 million in 2022, then skyrocketed by 190.6% to $1.8 million in 2023, then plummeted by 324.79% to -$4.1 million in 2024, then skyrocketed by 40.37% to -$2.4 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's EBT are -$2.4 million (Q3 2025), -$6.1 million (Q2 2025), and -$7.3 million (Q1 2025).